Ocugen, Inc. (OCGN) Latest Company News

Nov 4, 2026, 14:56 UTC
Ocugen, Inc. reported a third-quarter loss of $0.06 per share, compared with a loss of $0.07 per share a year earlier, in line with the consensus estimate.
Source:
- zacks.com
Nov 4, 2026, 12:00 UTC
Ocugen, Inc. executed an exclusive license agreement for OCU400 in the Middle East and North Africa with Roots Pharmaceutical.
Source:
- globenewswire.com
Nov 4, 2026, 12:00 UTC
Ocugen, Inc. executed an agreement with Global Alliance for Regenerative Medicine to coordinate and manage patient care for OCU400 in The Bahamas.
Source:
- globenewswire.com
Nov 4, 2026, 12:00 UTC
Ocugen, Inc. reported $84.6 million in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2026, with expected runway into 2028.
Source:
- globenewswire.com
Oct 22, 2026, 11:00 UTC
Ocugen, Inc. announced that it will report its third-quarter 2026 financial results and provide a business update on November 4, 2026.
Source:
- globenewswire.com
Oct 15, 2026, 10:27 UTC
Ocugen agreed to manufacture and supply the licensed OCU400 product to Roots Pharmaceutical Company WLL.
Oct 14, 2026, 10:30 UTC
Ocugen, Inc. announced a licensing agreement granting Roots Pharmaceutical and its strategic partner Al-Dhow International Holding exclusive rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa.
Source:
- globenewswire.com
Oct 1, 2026, 20:15 UTC
The Third Circuit abrogated the Oran-Burlington rule and vacated the dismissal of a securities fraud class action against Ocugen, Inc. and its chief executive, returning the case to the district court.
Source:
- investmentnews.com
Sep 10, 2026, 12:12 UTC
SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.
Source:
- globenewswire.com
Aug 6, 2026, 14:51 UTC
Ocugen reported a quarterly loss of $0.07 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.05.
Source:
Aug 6, 2026, 11:02 UTC
Ocugen closed a $130.0 million convertible senior notes financing, extending cash runway into 2028.
Source:
- globenewswire.com
Aug 6, 2026, 11:02 UTC
Ocugen strengthened its leadership team with the appointment of Mohamed Genead, M.D.
Source:
- globenewswire.com
Aug 6, 2026, 00:00 UTC
Ocugen, Inc. used $32.7 million of the convertible notes proceeds to retire a loan from Avenue Capital.
Jul 13, 2026, 11:02 UTC
Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 gene therapy for retinitis pigmentosa in the Middle East and North Africa region.
Source:
- globenewswire.com
- globenewswire.com
Jun 3, 2026, 00:00 UTC
Ramesh Ramachandran resigned as Chief Accounting Officer of Ocugen, Inc., effective May 29, 2026, and Rita Johnson-Greene was appointed as principal accounting officer, effective June 3, 2026.
May 7, 2026, 00:00 UTC
Ocugen, Inc. signed a private offering of $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034, convertible into Ocugen common stock, with net proceeds of approximately $99.5 million, of which about $32.7 million will be used to repay an existing loan.

OCGN

Ocugen, Inc. reported a third-quarter loss of $0.06 per share, compared with a loss of $0.07 per share a year earlier, in line with the consensus estimate.

Ocugen, Inc. executed an exclusive license agreement for OCU400 in the Middle East and North Africa with Roots Pharmaceutical.

Ocugen, Inc. executed an agreement with Global Alliance for Regenerative Medicine to coordinate and manage patient care for OCU400 in The Bahamas.

Ocugen, Inc. reported $84.6 million in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2026, with expected runway into 2028.

Ocugen, Inc. announced that it will report its third-quarter 2026 financial results and provide a business update on November 4, 2026.

Ocugen agreed to manufacture and supply the licensed OCU400 product to Roots Pharmaceutical Company WLL.

Ocugen, Inc. announced a licensing agreement granting Roots Pharmaceutical and its strategic partner Al-Dhow International Holding exclusive rights to OCU400 for retinitis pigmentosa in the Middle East and North Africa.

The Third Circuit abrogated the Oran-Burlington rule and vacated the dismissal of a securities fraud class action against Ocugen, Inc. and its chief executive, returning the case to the district court.

SCYNEXIS Inc. appointed Sanjay Subramanian as Chief Financial Officer effective September 9, 2026.

Ocugen reported a quarterly loss of $0.07 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.05.

Ocugen closed a $130.0 million convertible senior notes financing, extending cash runway into 2028.

Ocugen strengthened its leadership team with the appointment of Mohamed Genead, M.D.

Ocugen, Inc. used $32.7 million of the convertible notes proceeds to retire a loan from Avenue Capital.

Ocugen signed a binding term sheet with Roots Pharmaceutical to license OCU400 gene therapy for retinitis pigmentosa in the Middle East and North Africa region.

Ramesh Ramachandran resigned as Chief Accounting Officer of Ocugen, Inc., effective May 29, 2026, and Rita Johnson-Greene was appointed as principal accounting officer, effective June 3, 2026.

Ocugen, Inc. signed a private offering of $115.0 million aggregate principal amount of 6.75% convertible senior notes due 2034, convertible into Ocugen common stock, with net proceeds of approximately $99.5 million, of which about $32.7 million will be used to repay an existing loan.